echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet: Capecitabine beat adjuvant therapy significantly improves the survival prognosis of patients with advanced nasopharyngeal carcinoma

    Lancet: Capecitabine beat adjuvant therapy significantly improves the survival prognosis of patients with advanced nasopharyngeal carcinoma

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Although the proportion of patients with locally advanced nasopharyngeal carcinoma who have received standard treatment (such as final concurrent radiochemotherapy with or without induction chemotherapy) is very high, the risk of disease recurrence is still high


    Although the proportion of patients with locally advanced nasopharyngeal carcinoma who have achieved complete clinical remission after receiving standard treatment is high, the risk of disease recurrence is still high

    This is a multi-center, open-label, parallel-group, randomized controlled Phase 3 trial conducted in 14 hospitals in China.


    Receive oral capecitabine rhythm chemotherapy or follow-up observation

    From January 25, 2017 to October 25, 2018, a total of 675 patients were screened , of which 406 were recruited and randomly assigned to capecitabine group (n=204) or standard treatment group (n=202) )


    Screening

    A) survival rate without treatment failure; B) overall survival rate; C) survival rate without remote failure; D) survival rate without local failure

    A) survival rate without treatment failure; B) overall survival rate; C) survival rate without remote failure; D) survival rate without local failure

    After a median follow-up of 28 months (range 33-42), 29 relapses or deaths occurred in the capecitabine group (14%), while 53 cases (26%) occurred in the standard treatment group


    After a median follow-up of 28 months (range 33-42), 29 relapses or deaths occurred in the capecitabine group (14%), while 53 cases (26%) occurred in the standard treatment group

    Adverse events

    Adverse events

    35 cases (17%) of grade 3 adverse events were reported in the capecitabine group, and 11 cases (6%) were reported in the standard treatment group


    The study showed that the addition of beat-assisted capecitabine to radiotherapy and chemotherapy significantly improved the treatment failure-free survival rate of high-risk locally advanced nasopharyngeal carcinoma patients, and the safety was controllable


    The addition of beat-assisted capecitabine to radiotherapy and chemotherapy significantly improves the treatment failure-free survival rate of high-risk locally advanced nasopharyngeal carcinoma patients, and the safety is controllable

    Original source:

    Original source:

    Yu-Pei Chen, et al.


    Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.